Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Return on Capital Employed (2022 - 2025)

Prime Medicine filings provide 4 years of Return on Capital Employed readings, the most recent being 63.83% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed rose 922.0% to 63.83% in Q4 2025 year-over-year; TTM through Dec 2025 was 63.83%, a 922.0% increase, with the full-year FY2025 number at 73.71%, up 2376.0% from a year prior.
  • Return on Capital Employed hit 63.83% in Q4 2025 for Prime Medicine, up from 68.68% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 43.42% in Q1 2023 to a low of 127.94% in Q4 2023.
  • Median Return on Capital Employed over the past 4 years was 74.14% (2025), compared with a mean of 74.92%.
  • Biggest five-year swings in Return on Capital Employed: plummeted -8330bps in 2023 and later soared 5489bps in 2024.
  • Prime Medicine's Return on Capital Employed stood at 44.64% in 2022, then tumbled by -187bps to 127.94% in 2023, then soared by 43bps to 73.04% in 2024, then increased by 13bps to 63.83% in 2025.
  • The last three reported values for Return on Capital Employed were 63.83% (Q4 2025), 68.68% (Q3 2025), and 75.78% (Q2 2025) per Business Quant data.